Acquisitions momentum Lockwood has actively expanded through multiple acquisitions in recent years, including Research To Practice and IDEO Hematology, and most recently Total Health Oncology. This indicates a growth and integration strategy that may create cross-sell opportunities across medical education, oncology focus, and omnichannel engagement capabilities.

Oncology focus The firm increasingly strengthens oncology education and engagement capabilities, evidenced by acquisitions in oncology-focused providers and a prominent presence in accredited oncology medical education. This positions Lockwood to pursue pharma and biotech partners seeking specialized oncology medical communications, education, and clinician engagement programs.

Global health platform As a global health care services platform with a broad suite of capabilities (medical communications, education, animation, regulatory and clinical consulting, market access), Lockwood can cross-sell integrated solutions to large pharma clients seeking end-to-end support across development stages and markets.

Strong industry standing Recognition such as ISMPP President's Award and a Best Place to Work designation reflect credibility and strong culture, which can be leveraged in outreach to enterprise pharma partners prioritizing trusted vendors with proven quality, regulatory-compliant communications, and talent retention.

Financial scale Revenue footprint indicated at a substantial scale (500M to 1B) with 201-500 employees suggests capacity to handle large, multi-channel programs and long-term partnerships, offering potential for multi-year, multi-brand engagements and cross-divisional collaborations.